Mr. Hampton joined Currax Pharmaceuticals in April of 2019 as President and Chief Executive Officer and serves on its board of directors.  Prior to joining Currax, Mr. Hampton served as executive vice president, primary care business for Horizon Pharmaceuticals, (HZNP).  Previously, Mr. Hampton served as executive vice president, global orphan business unit and international operations for Horizon Pharmaceuticals. Additionally, he served as a member on Horizon Pharmaceuticals Executive Committee.  He has over 30 years of experience as a successful executive in the pharmaceutical and biotechnology field on both a national and international scale including specific expertise in rare disease (ACTIMMUNE, RAVICTI, PROCYSBI), autoimmune (HUMIRA), primary care, orthopedic (CELEBREX), diabetes (BYETTA), anti-infectives and cardiovascular spaces. This includes roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott (now AbbVie), Amylin and Horizon Pharmaceuticals. Mr. Hampton earned his Bachelor of Science from Miami University in Oxford, Ohio. He currently serves on the board of the Nashville Health Care Council and had previously served on the board of numerous public companies including Amryt Pharma Plc (AMYT) and IMAC (Nasdaq: IMAC) regeneration medical centers.